Phase 2 N=45 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
NF1 · Neurofibromatosis · Plexiform Neurofibromas
Primary: The Change in Tumor Size Based on Radiographic Assessment — -15.7; -4.1 mm^3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Primary: Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) — 6.8 percentage of participants
Phase 2 N=30 A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
BK Virus Infection
Primary: Time (Weeks) to Decrease of BKV Plasma Viral Load by 1 Log — 19.61; 10.80; 18.25 Weeks — p=0.1866
Phase 2 N=302 Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score — -49.38; -41.63; -55.70; -47.40 percent change — p=0.4498
Phase 2 N=82 Cockroach Immunotherapy in Children and Adolescents
Persistent Asthma
Primary: Change in Mean Total Nasal Symptom Score (TNSS) From Baseline to 12 Months Between Cockroach SCIT and Placebo — -1.02; -0.79 score on a scale — p=0.63
Phase 2 N=12 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)
High Tumor Mutation Burden · High TMB (Tumor Mutation Burden) · MSS (Microsatellite Stable)
Primary: Objective Response Rate (ORR) in Patients With MSI (Microsatellite Unstable)-Negative Solid Tumor Malignancies With a Mutator Phenotype — 5 Participants
Phase 2 N=151 Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Diffuse Astrocytoma · Anaplastic Astrocytoma · Astrocytoma
Primary: LGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using Response Assessment in Neuro-Oncology (RANO) Criteria — 46.6; 10.8 Percentage of…
Phase 2 N=50 A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis
Hyperhidrosis
Primary: Number of Treatment Emergent Adverse Events by Severity — 14; 4; 3; 0 Number of Events by Severity
Phase 2 N=65 High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
Multiple Myeloma
Primary: To Estimate the Response at Day 100 Following Transplant (Rate of CR) — 26; 32; 7 Participants
Phase 2 N=141 Flushing Reduction Associated With Nitrates
Menopausal Hot Flashes
Primary: Change From Baseline Hot Flash Frequency — -4.56; -4.02 Hot flashes per day — p=0.34
Phase 2 N=212 A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Pan Tumor
Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm A — 22.5; 38.6 Precentage of participants
Phase 2 N=164 Caring Light Project for Family Caregivers
Alzheimer Disease
Primary: Center for Epidemiological Studies Depression Scale — 17.72; 21.70 units on a scale
Phase 2 N=143 A 6 Month Safety Extension Study of MBGS205
Hypogonadotropic Hypogonadism
Primary: Percent Change in Bone Mineral Density Measured by DEXA (g/cm^2) From Baseline in Study MBGS205 to Week 48 in Study MBGS206 — -2.24; -3.31; -1.68 Percentage change
Phase 2 N=156 Virtual Patient Behavioral Response Training for Family Caregivers
Alzheimer Disease
Primary: Revised Memory and Behavior Problems Checklist — 0.66; 0.89 units on a scale
Phase 2 N=341 A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
Depressive Episode · Bipolar 1 Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -19.485; -19.324; -16.196 units on a scale — p=0.044